Summary
The first quarter of 2017 witnessed a surge in Securities Class Action filings. In addition, merger objection litigation continued at a relatively high rate. A significant driver of this has been the prominence of litigation involving companies in the pharmaceutical and biotech industries. The April 27th Webinar discussed differences between the two industries and the drivers of litigation.
Caroline Bullerjahn, a Partner in Goodwin's Securities Litigation and White Collar Defense Group, was a featured panelist.
Speakers
- /en/people/b/bullerjahn-caroline
Caroline H. Bullerjahn
PartnerCo-Chair, Complex Litigation & Dispute Resolution